Boston Trust Walden Corp Sells 12,345 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Boston Trust Walden Corp decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 819,282 shares of the company's stock after selling 12,345 shares during the quarter. Boston Trust Walden Corp owned 1.65% of Prestige Consumer Healthcare worth $70,434,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. QRG Capital Management Inc. raised its stake in Prestige Consumer Healthcare by 8.6% during the first quarter. QRG Capital Management Inc. now owns 5,971 shares of the company's stock worth $513,000 after acquiring an additional 475 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in Prestige Consumer Healthcare during the first quarter worth about $38,000. NorthCrest Asset Manangement LLC acquired a new position in Prestige Consumer Healthcare during the first quarter worth about $651,000. GAMMA Investing LLC raised its stake in Prestige Consumer Healthcare by 35.9% during the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock worth $162,000 after acquiring an additional 496 shares in the last quarter. Finally, Portside Wealth Group LLC raised its stake in Prestige Consumer Healthcare by 11.5% during the first quarter. Portside Wealth Group LLC now owns 8,000 shares of the company's stock worth $688,000 after acquiring an additional 828 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $83.51 on Thursday. The business has a 50 day moving average of $83.85 and a 200-day moving average of $82.55. Prestige Consumer Healthcare Inc. has a 1 year low of $64.63 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. The company has a market capitalization of $4.13 billion, a P/E ratio of 19.47, a P/E/G ratio of 2.51 and a beta of 0.45.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The company had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. During the same quarter in the prior year, the firm posted $1.02 earnings per share. The firm's revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on PBH shares. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.